Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
Panagiotis Bargiotas, Spyridon KonitsiotisDepartment of Neurology, University of Ioannina, Ioannina, GreeceAbstract: Parkinson’s disease therapy is still focused on the use of l-3,4-dihydroxyphenylalanine (levodopa or l-dopa) for the symptomatic treatment of the main clinical features of t...
Guardado en:
Autores principales: | Bargiotas P, Konitsiotis S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/748b0b5b4e2c4f8ea983c472fcb6463b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease
por: Yang X, et al.
Publicado: (2013) -
Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats
por: Shi H, et al.
Publicado: (2015) -
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: David J Brooks
Publicado: (2008) -
Treatment of neurolept-induced tardive dyskinesia
por: Jankelowitz SK
Publicado: (2013) -
The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu N, et al.
Publicado: (2018)